|Cytokinetics Reports Top-Line Results from BENEFIT-ALS; Neurocrine Announces Conference Call And Webcast|
|By Staff and Wire Reports|
|Friday, 25 April 2014 18:46|
Cytokinetics, Incorporated (Nasdaq: CYTK) announced the top-line results of BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). Detailed results will be presented during the 66th Annual Meeting of the American Academy of Neurology (AAN) on Tuesday, April 29th at the Pennsylvania Convention Center in Philadelphia, PA.
BENEFIT-ALS did not achieve its primary efficacy endpoint, the mean change from baseline in the ALS Functional Rating Scale in its revised form (ALSFRS-R) on tirasemtiv versus placebo (-2.98 points in the tirasemtiv group versus -2.40 points in the placebo group, p = 0.11). Secondary efficacy analyses of the effect of tirasemtiv on respiratory function and other measures of skeletal muscle function produced mixed results.
"Patients with ALS desperately need new therapeutic alternatives to slow the course of their disease and loss of function. We stand with the ALS community in our disappointment that BENEFIT-ALS did not achieve its primary efficacy endpoint," stated Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "The results from BENEFIT-ALS are just now becoming available to our team at Cytokinetics and will be shared in more detail with the broader scientific and medical community focused to research in ALS in the next few days. Understanding these results will require significant further review. Once we have fully evaluated the data from BENEFIT-ALS, we expect to determine whether there is a potential development path forward for tirasemtiv for the potential treatment of ALS and what may be the appropriate next steps."
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced the Company will report its first quarter 2014 financial results after the Nasdaq market closes on Wednesday, April 30, 2014. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday afternoon, April 30, 2014 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Participants can access the live conference call by dialing 866-952-1908 (US) or 785-424-1827 (International) using the conference ID: NBIX. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com.
If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. A replay of the conference call will be available approximately one hour after the conclusion of the call by dialing 800-695-2533 (US) or 402-530-9029 (International) using the conference ID: NBIX. The call will be archived for one month.
Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.
Amedisys, Inc. (Nasdaq:AMED), one of America's leading home health and hospice care companies, announced today that it will host a conference call to discuss results for the first quarter ended on March 31, 2014 on Thursday, May 8, 2014 at 10:00 a.m. Eastern Time (9:00 a.m. Central Time).
Baxano Surgical, Inc. (Nasdaq:BAXS) announced today that it plans to release first quarter 2014 financial and operating results after market close on Thursday, May 8, 2014.
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, will be participating in the Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists (ACOG), being held April 26-30 at the McCormick Place Convention Center in Chicago, Illinois.
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that the Company will report its first quarter financial results on Tuesday, May 6, 2014 after the close of the financial markets.
LifeVantage Corporation (Nasdaq:LFVN), a company dedicated to helping people achieve healthy living through a combination of a compelling business opportunity and scientifically validated products, has launched a revolutionary beauty system consisting of a full line of anti-aging skin care products with enhanced Nrf2 technologies under its existing TrueScience brand.
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced that trading of Lombard Medical, Inc. (Nasdaq:EVAR), the specialist medical device company focused on endovascular aortic repair of abdominal aortic aneurysms, commenced on The NASDAQ Stock Market on April 25, 2014.
M Line Holdings, Inc. (OTCQB:MLHC), a leading provider of products, assemblies and services to the precision high tech segment of both the aerospace and medical industries as well as a seller of high end pre-owned Japanese Computer Numerically Controlled ("CNC") Equipment, announces that WallStreetCorner.com has issued a research report on MLHC.
Medical Marijuana Sciences, Inc. (MMS), a subsidiary of Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Mark L. Rabe, MD, ABIHM, the Scientific Advisory Board Chairman of MMS, delivered a "Pain Medicine Grand Rounds" presentation to pain specialists and other physicians at the University of California, San Diego (UCSD) that dealt with the medicinal properties of constituents of Cannabis (marijuana) that are known as cannabinoids.
Natural Health Trends Corp. (OTCQB:NHTC), a leading direct selling company that markets premium quality personal care, wellness and "quality of life" products under the NHT Global brand, today announced that management will conduct a conference call to discuss its financial results for the quarter ended March 31, 2014.
Quotient Limited (Nasdaq:QTNTU), an established, commercial-stage diagnostics company, today announced the pricing of its initial public offering of 5,000,000 units, each consisting of one ordinary share and one warrant to purchase 0.8 of one ordinary share, at a price of $8.00 per unit.
Radnet Management, Inc. and its parent, RadNet, Inc. (Nasdaq:RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 250 owned and/or operated outpatient imaging centers, today announced the completion of the previously announced redemption of all of Radnet Management's remaining outstanding 10 3/8% Senior Notes due 2018.
Repligen Corporation (Nasdaq:RGEN) today announced that it will report first quarter 2014 financial results on Thursday, May 8, 2014.
Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP), a global biopharmaceutical company, today announced that preclinical data for lubiprostone and unoprostone isopropyl will be presented at the Experimental Biology Society 2014 Conference in San Diego, California.